Zydus Lifesciences Limited will declare its financial results for the first quarter of fiscal year 2026-27 (Q1 FY27) on Tuesday, August 11, 2026. The company has scheduled a post-results Q&A session via webinar later that day at 4:00 PM IST to discuss performance with investors and analysts. This disclosure ensures market participants have timely access to management commentary following the release of key financial metrics for the April-June 2026 period.

The earnings call will be hosted by Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited. Participants can join the webinar by pre-registering through the provided link or accessing the Zoom platform directly. The company emphasized that the audio recording of the call will be made available on its website pursuant to regulatory requirements, ensuring transparency and accessibility for all stakeholders.

Regulatory Compliance and Disclosure

In compliance with Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Zydus Lifesciences Limited has notified the exchanges of the event details. The audio recording of the earnings call will be hosted on the Company's investor relations page at https://www.zyduslife.com/investorzone . Additionally, a transcript of the discussion will be published subsequently on the same platform.

Key Event Details

Investors are advised to pre-register using the link provided in the official notice to ensure seamless access to the session. The Q1 FY27 Earnings Presentation will also be available on the Company's website post-results announcement.

Additional Resources

Shareholders and analysts may refer to the FY26 Annual Report of the Company, which is accessible via the investor zone. The report provides comprehensive insights into the previous fiscal year's performance, serving as a baseline for evaluating the upcoming quarterly results. The notice was issued by Dhaval N. Soni, Company Secretary and Compliance Officer, on July 30, 2026.

Zydus Lifesciences Limited faces a financial liability of ₹108.54 million after the Office of the Superintendent of Stamps, Gandhinagar, issued an order dated July 22, 2026, alleging short payment of stamp duty on a recent asset acquisition. The authority determined that the market value of land, buildings, plant, and machinery acquired from Sterling Biotech Limited, a joint venture company, was ₹1,542.60 million, which exceeded the value adopted for stamp duty purposes. This valuation discrepancy led to a demand for ₹53.47 million in deficient duty and ₹55.07 million in penalties, impacting the company’s regulatory compliance obligations.

The disclosure was made under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI Master Circular dated January 30, 2026. Zydus Lifesciences received the direction at 15:58 hours on July 28, 2026. The order specifically cites alleged deficiencies in the Sale Deed executed for the transaction, noting that certain details relating to construction area and consideration were not fully reflected in the registration documents submitted.

Breakdown of Financial Demand

The total demand comprises deficient stamp duty and penalties levied under specific state rules and acts. The components are detailed below:

The penalty structure indicates a significant regulatory stance, with the primary penalty mirroring the amount of the deficient duty. The additional penalty of ₹1.60 million relates to procedural non-compliance under the Gujarat Stamp Act.

What the Numbers Show

The core issue stems from a divergence between the transaction value used for stamping and the market value assessed by the Gandhinagar stamps office. By valuing the assets at ₹1,542.60 million, the authority effectively redefined the tax base for the acquisition from Sterling Biotech Limited. This suggests that internal valuation metrics or negotiated prices may not align with government-prescribed market values for industrial assets in Gujarat. The company is currently evaluating the order and assessing appropriate legal remedies, indicating that the liability is not yet settled and may be contested.

The filing was signed by Dhaval N. Soni, Company Secretary and Compliance Officer, confirming the formal notification to the exchanges. The matter remains open as the company reviews its legal options.